Comparison of grapiprant and meloxicam for management of postoperative joint pain in dogs: A randomized, double‐blinded, prospective clinical trial

• DOI: 10.1111/jvim.17136
• Publication Date: 2024-06-30T04:29:41Z
• Authors: Anaelle Cassemiche; Sarah Schoffit; Mathieu Manassero; Matthias Kohlhauer
• Keywords: Meloxicam; Clinical endpoint

Abstract Background Grapiprant is a novel anti‐inflammatory drug approved for the treatment of pain associated with osteoarthritis in dogs. Objective Compare efficacy grapiprant vs meloxicam management postoperative joint Animals Forty‐eight dogs presented cranial cruciate ligament disease and treated by tibial plateau leveling osteotomy (TPLO) between May 2020 2022. Methods In this randomized, double blinded, prospective clinical trial, client‐owned naturally occurring unilateral rupture were enrolled on day surgery. The after surgery, all animals received subcutaneous injection 0.2 mg/kg randomly assigned to receive either oral (2 mg/kg) or (0.1 mg/kg), once 14 days, blinded manner. primary endpoint study was severity (PSS) interference (PIS) scores, assessed Canine Brief Pain Inventory (CBPI) at 3, 7, 10 15 Results Three days had lower PSS compared mean ± SD 2.76 0.18 3.25 0.23, respectively (difference −0.49 [95% CI −0.94 −0.04], P = .032). Interference Score also group 3 (4.11 4.69 0.16 [difference −0.58 {95% −1.03 −0.13}, .013]) (2.23 0.13 2.72 0.28 −0.92 −0.01}, .049]). Conclusions Clinical Importance Our supports use as an alternative analgesic